Vanguard Group’s Citius Pharmaceuticals CTXR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $155K | Buy |
199,258
+32,868
| +20% | +$41.1K | ﹤0.01% | 4135 |
|
|
2025
Q3 | $206K | Buy |
166,390
+86,287
| +108% | +$120K | ﹤0.01% | 4128 |
|
|
2025
Q2 | $127K | Sell |
80,103
-177,528
| -69% | -$163K | ﹤0.01% | 4126 |
|
|
2025
Q1 | $384K | Hold |
257,631
| – | – | ﹤0.01% | 3938 |
|
|
2024
Q4 | $1.03M | Sell |
257,631
-2
| -0% | -$13 | ﹤0.01% | 3753 |
|
|
2024
Q3 | $3.23M | Buy |
257,633
+4,543
| +2% | +$76.4K | ﹤0.01% | 3417 |
|
|
2024
Q2 | $3.69M | Sell |
253,090
-27,115
| -10% | -$486K | ﹤0.01% | 3378 |
|
|
2024
Q1 | $6.29M | Buy |
280,205
+4,196
| +2% | +$76.6K | ﹤0.01% | 3203 |
|
|
2023
Q4 | $5.22M | Buy |
276,009
+2,909
| +1% | +$55.2K | ﹤0.01% | 3272 |
|
|
2023
Q3 | $4.67M | Buy |
273,100
+5,855
| +2% | +$139K | ﹤0.01% | 3281 |
|
|
2023
Q2 | $8.02M | Buy |
267,245
+25,072
| +10% | +$825K | ﹤0.01% | 3071 |
|
|
2023
Q1 | $7.08M | Buy |
242,173
+1,612
| +0.7% | +$46.5K | ﹤0.01% | 3141 |
|
|
2022
Q4 | $4.75M | Buy |
240,561
+7,963
| +3% | +$217K | ﹤0.01% | 3334 |
|
|
2022
Q3 | $7.04M | Buy |
232,598
+3,184
| +1% | +$87.5K | ﹤0.01% | 3127 |
|
|
2022
Q2 | $5.28M | Sell |
229,414
-19,252
| -8% | -$528K | ﹤0.01% | 3356 |
|
|
2022
Q1 | $11.1M | Buy |
248,666
+1,602
| +0.6% | +$63.3K | ﹤0.01% | 3090 |
|
|
2021
Q4 | $9.51M | Buy |
247,064
+15,933
| +7% | +$723K | ﹤0.01% | 3235 |
|
|
2021
Q3 | $11.7M | Buy |
231,131
+5,018
| +2% | +$252K | ﹤0.01% | 3148 |
|
|
2021
Q2 | $19.7M | Buy |
226,113
+23,464
| +12% | +$1.41M | ﹤0.01% | 2855 |
|
|
2021
Q1 | $9.02M | Buy |
202,649
+172,444
| +571% | +$6.87M | ﹤0.01% | 3206 |
|
|
2020
Q4 | $770K | Buy |
30,205
+7,287
| +32% | +$190K | ﹤0.01% | 3890 |
|
|
2020
Q3 | $596K | Buy |
22,918
+1,344
| +6% | +$38K | ﹤0.01% | 3780 |
|
|
2020
Q2 | $609K | Buy |
21,574
+2,998
| +16% | +$65.6K | ﹤0.01% | 3725 |
|
|
2020
Q1 | $279K | Sell |
18,576
-113
| -0.6% | -$2.39K | ﹤0.01% | 3803 |
|
|
2019
Q4 | $477K | Hold |
18,689
| – | – | ﹤0.01% | 3808 |
|
|
2019
Q3 | $360K | Buy |
18,689
+563
| +3% | +$14.8K | ﹤0.01% | 3872 |
|
|
2019
Q2 | $444K | Buy |
18,126
+13,687
| +308% | +$390K | ﹤0.01% | 3846 |
|
|
2019
Q1 | $158K | Buy |
4,439
+2,280
| +106% | +$67.1K | ﹤0.01% | 3957 |
|
|
2018
Q4 | $56K | Buy |
2,159
+54
| +3% | +$1.85K | ﹤0.01% | 4062 |
|
|
2018
Q3 | $90K | Buy |
2,105
+140
| +7% | +$6.69K | ﹤0.01% | 4088 |
|
|
2018
Q2 | $113K | Buy |
1,965
+923
| +89% | +$61.3K | ﹤0.01% | 4040 |
|
|
2018
Q1 | $81K | Buy |
1,042
+600
| +136% | +$55.2K | ﹤0.01% | 4047 |
|
|
2017
Q4 | $43K | Buy |
+442
| New | +$44.3K | ﹤0.01% | 4035 |
|
Other funds holding CTXR
HCM
XT
AAG
TSS
Vanguard Group's CTXR Position: Q4 2025 in Review
Vanguard Group increased its Citius Pharmaceuticals (CTXR) stake by 20% in Q4 2025, buying an estimated $41.1K and bringing the position to 199,258 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #4135.
Vanguard Group first reported a position in CTXR in Q4 2017 and has held it in 33 quarters since. The position peaked at $19.7M in Q2 2021. 39 funds tracked by Wall St. Rank hold CTXR as of Q4 2025.
- Vanguard Group held 199,258 shares of Citius Pharmaceuticals worth $155K as of Q4 2025.
- Vanguard Group bought 32,868 Citius Pharmaceuticals shares in Q4 2025, an estimated $41.1K.
- Citius Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4135 holding.
- Vanguard Group first reported a position in Citius Pharmaceuticals in Q4 2017 and has held it in 33 quarters since.
- Vanguard Group's Citius Pharmaceuticals position peaked at $19.7M in Q2 2021.
- 39 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.